On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging

A Adamiano, M Iafisco, M Sandri, M Basini, P Arosio, T Canu, G Sitia, A Esposito, V Iannotti, G Ausanio, E Fragogeorgi, M Rouchota, G Loudos, A Lascialfari, A Tampieri

Research output: Contribution to journalArticle

Abstract

The identification of alternative biocompatible magnetic NPs for advanced clinical application is becoming an important need due to raising concerns about iron accumulation in soft issues associated to the administration of superparamagnetic iron oxide nanoparticles (NPs). Here, we report on the performance of previously synthetized iron-doped hydroxyapatite (FeHA) NPs as contrast agent for magnetic resonance imaging (MRI). The MRI contrast abilities of FeHA and Endorem® (dextran coated iron oxide NPs) were assessed by 1 H nuclear magnetic resonance relaxometry and their performance in healthy mice was monitored by a 7 Tesla scanner. FeHA applied a higher contrast enhancement, and had a longer endurance in the liver with respect to Endorem® at iron equality. Additionally, a proof of concept of FeHA use as scintigraphy imaging agent for positron emission tomography (PET) and single photon emission computed tomography (SPECT) was given labeling FeHA with 99m Tc-MDP by a straightforward surface functionalization process. Scintigraphy/x-ray fused imaging and ex vivo studies confirmed its dominant accumulation in the liver, and secondarily in other organs of the mononuclear phagocyte system. FeHA efficiency as MRI-T 2 and PET-SPECT imaging agent combined to its already reported intrinsic biocompatibility qualifies it as a promising material for innovative nanomedical applications. Statement of Significance: The ability of iron-doped hydroxyapatite nanoaprticles (FeHA) to work in vivo as imaging agents for magnetic resonance (MR) and nuclear imaging is demonstrated. FeHA applied an higher MR contrast in the liver, spleen and kidneys of mice with respect to Endorem®. The successful radiolabeling of FeHA allowed for scintigraphy/X-ray and ex vivo biodistribution studies, confirming MR results and envisioning FeHA application for dual-imaging. © 2018 Acta Materialia Inc.
Original languageEnglish
Pages (from-to)458-469
Number of pages12
JournalActa Biomaterialia
Volume73
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Durapatite
Hydroxyapatite
Nanoparticles
Iron
Magnetic Resonance Imaging
Radionuclide Imaging
Magnetic resonance
Imaging techniques
Magnetic Resonance Spectroscopy
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Liver
X-Rays
Technetium Tc 99m Medronate
Single photon emission computed tomography
Mononuclear Phagocyte System
Positron emission tomography
Dextrans
Contrast Media
Iron oxides

Cite this

On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging. / Adamiano, A; Iafisco, M; Sandri, M; Basini, M; Arosio, P; Canu, T; Sitia, G; Esposito, A; Iannotti, V; Ausanio, G; Fragogeorgi, E; Rouchota, M; Loudos, G; Lascialfari, A; Tampieri, A.

In: Acta Biomaterialia, Vol. 73, No. 3, 2018, p. 458-469.

Research output: Contribution to journalArticle

Adamiano, A, Iafisco, M, Sandri, M, Basini, M, Arosio, P, Canu, T, Sitia, G, Esposito, A, Iannotti, V, Ausanio, G, Fragogeorgi, E, Rouchota, M, Loudos, G, Lascialfari, A & Tampieri, A 2018, 'On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging', Acta Biomaterialia, vol. 73, no. 3, pp. 458-469. https://doi.org/10.1016/j.actbio.2018.04.040
Adamiano, A ; Iafisco, M ; Sandri, M ; Basini, M ; Arosio, P ; Canu, T ; Sitia, G ; Esposito, A ; Iannotti, V ; Ausanio, G ; Fragogeorgi, E ; Rouchota, M ; Loudos, G ; Lascialfari, A ; Tampieri, A. / On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging. In: Acta Biomaterialia. 2018 ; Vol. 73, No. 3. pp. 458-469.
@article{08c9b256b0b64d6aa058c6a4b515c737,
title = "On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging",
abstract = "The identification of alternative biocompatible magnetic NPs for advanced clinical application is becoming an important need due to raising concerns about iron accumulation in soft issues associated to the administration of superparamagnetic iron oxide nanoparticles (NPs). Here, we report on the performance of previously synthetized iron-doped hydroxyapatite (FeHA) NPs as contrast agent for magnetic resonance imaging (MRI). The MRI contrast abilities of FeHA and Endorem{\circledR} (dextran coated iron oxide NPs) were assessed by 1 H nuclear magnetic resonance relaxometry and their performance in healthy mice was monitored by a 7 Tesla scanner. FeHA applied a higher contrast enhancement, and had a longer endurance in the liver with respect to Endorem{\circledR} at iron equality. Additionally, a proof of concept of FeHA use as scintigraphy imaging agent for positron emission tomography (PET) and single photon emission computed tomography (SPECT) was given labeling FeHA with 99m Tc-MDP by a straightforward surface functionalization process. Scintigraphy/x-ray fused imaging and ex vivo studies confirmed its dominant accumulation in the liver, and secondarily in other organs of the mononuclear phagocyte system. FeHA efficiency as MRI-T 2 and PET-SPECT imaging agent combined to its already reported intrinsic biocompatibility qualifies it as a promising material for innovative nanomedical applications. Statement of Significance: The ability of iron-doped hydroxyapatite nanoaprticles (FeHA) to work in vivo as imaging agents for magnetic resonance (MR) and nuclear imaging is demonstrated. FeHA applied an higher MR contrast in the liver, spleen and kidneys of mice with respect to Endorem{\circledR}. The successful radiolabeling of FeHA allowed for scintigraphy/X-ray and ex vivo biodistribution studies, confirming MR results and envisioning FeHA application for dual-imaging. {\circledC} 2018 Acta Materialia Inc.",
author = "A Adamiano and M Iafisco and M Sandri and M Basini and P Arosio and T Canu and G Sitia and A Esposito and V Iannotti and G Ausanio and E Fragogeorgi and M Rouchota and G Loudos and A Lascialfari and A Tampieri",
year = "2018",
doi = "10.1016/j.actbio.2018.04.040",
language = "English",
volume = "73",
pages = "458--469",
journal = "Acta Biomaterialia",
issn = "1742-7061",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - On the use of superparamagnetic hydroxyapatite nanoparticles as an agent for magnetic and nuclear in vivo imaging

AU - Adamiano, A

AU - Iafisco, M

AU - Sandri, M

AU - Basini, M

AU - Arosio, P

AU - Canu, T

AU - Sitia, G

AU - Esposito, A

AU - Iannotti, V

AU - Ausanio, G

AU - Fragogeorgi, E

AU - Rouchota, M

AU - Loudos, G

AU - Lascialfari, A

AU - Tampieri, A

PY - 2018

Y1 - 2018

N2 - The identification of alternative biocompatible magnetic NPs for advanced clinical application is becoming an important need due to raising concerns about iron accumulation in soft issues associated to the administration of superparamagnetic iron oxide nanoparticles (NPs). Here, we report on the performance of previously synthetized iron-doped hydroxyapatite (FeHA) NPs as contrast agent for magnetic resonance imaging (MRI). The MRI contrast abilities of FeHA and Endorem® (dextran coated iron oxide NPs) were assessed by 1 H nuclear magnetic resonance relaxometry and their performance in healthy mice was monitored by a 7 Tesla scanner. FeHA applied a higher contrast enhancement, and had a longer endurance in the liver with respect to Endorem® at iron equality. Additionally, a proof of concept of FeHA use as scintigraphy imaging agent for positron emission tomography (PET) and single photon emission computed tomography (SPECT) was given labeling FeHA with 99m Tc-MDP by a straightforward surface functionalization process. Scintigraphy/x-ray fused imaging and ex vivo studies confirmed its dominant accumulation in the liver, and secondarily in other organs of the mononuclear phagocyte system. FeHA efficiency as MRI-T 2 and PET-SPECT imaging agent combined to its already reported intrinsic biocompatibility qualifies it as a promising material for innovative nanomedical applications. Statement of Significance: The ability of iron-doped hydroxyapatite nanoaprticles (FeHA) to work in vivo as imaging agents for magnetic resonance (MR) and nuclear imaging is demonstrated. FeHA applied an higher MR contrast in the liver, spleen and kidneys of mice with respect to Endorem®. The successful radiolabeling of FeHA allowed for scintigraphy/X-ray and ex vivo biodistribution studies, confirming MR results and envisioning FeHA application for dual-imaging. © 2018 Acta Materialia Inc.

AB - The identification of alternative biocompatible magnetic NPs for advanced clinical application is becoming an important need due to raising concerns about iron accumulation in soft issues associated to the administration of superparamagnetic iron oxide nanoparticles (NPs). Here, we report on the performance of previously synthetized iron-doped hydroxyapatite (FeHA) NPs as contrast agent for magnetic resonance imaging (MRI). The MRI contrast abilities of FeHA and Endorem® (dextran coated iron oxide NPs) were assessed by 1 H nuclear magnetic resonance relaxometry and their performance in healthy mice was monitored by a 7 Tesla scanner. FeHA applied a higher contrast enhancement, and had a longer endurance in the liver with respect to Endorem® at iron equality. Additionally, a proof of concept of FeHA use as scintigraphy imaging agent for positron emission tomography (PET) and single photon emission computed tomography (SPECT) was given labeling FeHA with 99m Tc-MDP by a straightforward surface functionalization process. Scintigraphy/x-ray fused imaging and ex vivo studies confirmed its dominant accumulation in the liver, and secondarily in other organs of the mononuclear phagocyte system. FeHA efficiency as MRI-T 2 and PET-SPECT imaging agent combined to its already reported intrinsic biocompatibility qualifies it as a promising material for innovative nanomedical applications. Statement of Significance: The ability of iron-doped hydroxyapatite nanoaprticles (FeHA) to work in vivo as imaging agents for magnetic resonance (MR) and nuclear imaging is demonstrated. FeHA applied an higher MR contrast in the liver, spleen and kidneys of mice with respect to Endorem®. The successful radiolabeling of FeHA allowed for scintigraphy/X-ray and ex vivo biodistribution studies, confirming MR results and envisioning FeHA application for dual-imaging. © 2018 Acta Materialia Inc.

U2 - 10.1016/j.actbio.2018.04.040

DO - 10.1016/j.actbio.2018.04.040

M3 - Article

VL - 73

SP - 458

EP - 469

JO - Acta Biomaterialia

JF - Acta Biomaterialia

SN - 1742-7061

IS - 3

ER -